Transthyretin cardiomyopathy new drug Vyndamax has finally made progress. According to related industries, Vyndamax, a treatment for ATTR-CM (ATTR amyloidosis with cardiomyopathy) caused by Transthyretin amyloidosis in Pfizer, recently passed the HIRA Pharmaceutical Benefit Standards Subcommittee. This is the result of his fourth attempt. As a result, attention is being paid to whether Vyndamax can succeed in registering insurance benefits beyond the remaining hurdles.

Vyndamax failed to designate an essential drug in its first benefit challenge at the beginning of last year. After that, the second challenge was made through an economic evaluation in the first half of the same year and a risk sharing ag